Guidelines and management of global risk: The European perspective

European Heart Journal, Supplement

Volumn 6, Issue 3, 2004, Pages

  Hobbs, F D R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Coronary heart disease; Europe; Guidelines; Primary prevention; Risk factors; Secondary prevention

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; DATA ANALYSIS; DIABETES MELLITUS; GENERAL PRACTICE; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL PROFESSION; MEDICAL RECORD; MORBIDITY; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; WORKLOAD;

EID: 3042645182     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehjsup.2004.04.005     Document Type: Review

References (21)

1. Third Joint Task Force of European and other Societies of Cardiovascular disease. Prevention in Clinical Practice. European Guidelines on Cardiovascular disease prevention in clinical practice. European Heart Journal 2003;24:1601-1610
2. Wood D., De Backer G., Faergeman O., et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 140:1998;199-270
3. Pyörälä K., De Backer G., Graham I., et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J. 15:1994;1300-1331
4. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet. 349:1997;1498-1504
5. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet. 349:1997;1436-1442
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
7. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569-82
8. Pearson T.A., Laurora I., Chu H., et al. The lipid treatment assessment project (L-sTAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern. Med. 160:2000;459-467
9. EUROASPIRE Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72
10. van der Weijden T., Grol R.P., Knottnerus J.A. Feasibility of a national cholesterol guideline in daily practice. A randomized controlled trial in 20 general practices. Int. J. Qual. Health Care. 11:1999;131-137
11. Rutten G., van der Laan J. Hypercholesterolaemia: setting a Dutch national standard. Br. J. Gen. Pract. 42:1992;411-414
12. Grol R., Dalhuijsen J., Thomas S., et al. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ. 317:1998;858-861
13. Hobbs F.D.R., Erhardt L. Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey: physician perceptions and attitudes towards cholesterol guidelines. Eur. Heart J. 21:2000;477
14. Grover S.A., Lowensteyn I., Esrey K.L., et al. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ. 310:1995;975-978
15. Peters T.J., Montgomery A.A., Fahey T. How accurately do primary health care professionals use cardiovascular risk tables in the management of hypertension? Br. J. Gen. Pract. 49:1999;987-988
16. Erhardt L., Hobbs F.D.R. Reassessing European Attitudes about Cardiovascular Treatment (REACT) general population survey. Int J Clin Pract. 56(9):2002;638-644
17. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339:1998;229-234
18. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 21:1998;1414-1431
19. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
20. Armitage J., Collins R. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. Heart. 84:2000;357-360
21. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 285:2001;1711-1718